Siemens Healthineers - For FY 2027, Expect Comparable Revenue Growth Between 4.0% And 5.0% Over FY 2026

By Reuters News

- SIEMENS HEALTHINEERS AG SHLG.DE:

  • Q4 REVENUE UP 7.3% AT EUR 6.78 BILLION VERSUS CONSENSUS AT 6.74 BILLION

  • Q4 ADJUSTED EBIT MARGIN AT 15.9%

  • Q4 NET INCOME UP 0.3% AT EUR 599 MILLION

  • FOR FY 2027, EXPECT COMPARABLE REVENUE GROWTH BETWEEN 4.0% AND 5.0% OVER FY 2026

  • Q4 ADJUSTED EBIT DOWN 2% AT EUR 1.08 BILLION VERSUS CONSENSUS AT EUR 1.11 BILLION

  • FOR FY 2027 ADJUSTED BASIC EPS, WE EXPECT A RANGE OF BETWEEN €2.20 AND €2.40

  • CO WILL CHANGE ITS NAME TO 'HEALTHINEERS'

  • TO REBRAND IN VITRO DIAGNOSTICS BUSINESS AS OLYRIAN DIAGNOSTICS

  • INITIATED CARVE-OUT PROCESS FOR IN VITRO DIAGNOSTICS BUSINESS, IMPORTANT STEP TOWARD ESTABLISHING STANDALONE COMPANY

Further company coverage: SHLG.DE

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.